Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine
Oncology
Dr. Mamoru Shoji, MD
Mamoru Shoji is an expert in the field of Oncology. Mamoru Shoji has written publications. He has 21 publications published with PubMed. The lastest publication is: 'Inhibition of NF-B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.'
Publications
- Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.
- Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
- Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
- Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vi...
- Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109.
- Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993).
- Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
- Synthetic Curcumin Analog UBS Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts.
- Bioactive flavonoid p-hydroxycinnamic acid stimulates osteoblastogenesis and suppresses adipogenesis in bone marrow culture.
- Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition.
- Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.
- Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation.
- Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism.
- Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.
- Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa.
- Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system.
- EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism.
- Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
- Mitogen-actived protein kinase activation is an early event in melanoma progression.
- Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
Dr. Arielle C. Lutterman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Eley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric R. Anderson, MD |
|
|
Dr. Wayne B. Harris, MD
This Doctor is OpenDoctor Recommended.
|